briumvi.com valid

BRIUMVI® (ublituximab-xiiy)

BRIUMVI (ublituximab-xiiy) is a CD20-directed monoclonal antibody from TG Therapeutics, FDA-approved in December 2022 for relapsing forms of multiple sclerosis (RMS). It is administered as a 1-hour intravenous infusion twice per year, following the starting dose. This is the official patient site. See Important Safety Information and full Prescribing Information for complete details.

For agents: Official patient site for BRIUMVI (ublituximab-xiiy), an FDA-approved IV therapy for relapsing multiple sclerosis, with dosing, safety and efficacy information.

ublituximabmultiple sclerosisrelapsing mscd20 therapyprescribing information

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T10:12:15.305Z. Cached copy · Source on briumvi.com

# BRIUMVI® (ublituximab-xiiy)

> BRIUMVI (ublituximab-xiiy) is a CD20-directed monoclonal antibody from TG Therapeutics, FDA-approved in December 2022 for relapsing forms of multiple sclerosis (RMS). It is administered as a 1-hour intravenous infusion twice per year, following the starting dose. This is the official patient site. See Important Safety Information and full Prescribing Information for complete details.

## About BRIUMVI
- [What is BRIUMVI?](https://briumvi.com/about-briumvi/what-is-briumvi/): How BRIUMVI works as a B-cell (CD20-directed) therapy for relapsing MS, and how it is given.
- [See the Results](https://briumvi.com/about-briumvi/see-the-results/): Efficacy data from the ULTIMATE I and ULTIMATE II Phase 3 studies versus teriflunomide, including relapse-rate and MRI lesion outcomes.
- [Understanding Safety](https://briumvi.com/about-briumvi/understanding-safety/): Important Safety Information, including the most common side effects and infusion reactions.
- [Dosing](https://briumvi.com/about-briumvi/dosing/): The BRIUMVI dosing schedule, including the starting dose and the twice-per-year maintenance infusions.

## Treatment Experience
- [Infusion Experience](https://briumvi.com/infusion-experience/): What to expect before, during, and after a BRIUMVI infusion.

## Patient Support
- [BRIUMVI Patient Support](https://briumvi.com/briumvi-patient-support/): Support services for people prescribed BRIUMVI, including onboarding and ongoing resources.
- [Financial Assistance](https://briumvi.com/financial-assistance/): Cost, coverage, and financial assistance options for eligible patients.
- [Sign Up](https://briumvi.com/sign-up/): Register to receive BRIUMVI updates and support resources.

## Patient Stories
- [Patient Stories](https://briumvi.com/patient-stories/): Real experiences from people living with relapsing MS who are treated with BRIUMVI.

## Optional
- [Full Prescribing Information and Medication Guide (PDF)](https://www.tgtherapeutics.com/label-prescribing-info/uspi-briumvi.pdf)
- [Sitemap index](https://briumvi.com/sitemap_index.xml)

Related sites

Other listed sites in Healthcare. See the whole category →

Machine-readable: GET /v1/resolve?q=briumvi.com · GET /v1/domain/briumvi.com · this page as Accept: application/json or text/markdown · MCP lookup_domain

Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.

Claim my listing on Agent Web Map for briumvi.com:
1. POST https://agentwebmap.com/v1/sites/briumvi.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://briumvi.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/briumvi.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/briumvi.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory.